1.38
0.03 (2.22%)
| Penutupan Terdahulu | 1.35 |
| Buka | 1.36 |
| Jumlah Dagangan | 2,519,134 |
| Purata Dagangan (3B) | 3,980,491 |
| Modal Pasaran | 431,001,760 |
| Harga / Jualan (P/S) | 77.96 |
| Harga / Buku (P/B) | 131.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -979.14% |
| EPS Cair (TTM) | -0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 46.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 199.97% |
| Nisbah Semasa (MRQ) | 2.60 |
| Aliran Tunai Operasi (OCF TTM) | -50.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.58 M |
| Pulangan Atas Aset (ROA TTM) | -61.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -248.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ocugen, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.38 |
|
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA"). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.60% |
| % Dimiliki oleh Institusi | 26.48% |
| Julat 52 Minggu | ||
| Median | 7.00 (407.25%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 05 Mar 2026 | 7.00 (407.25%) | Beli | 1.94 |
| 20 Jan 2026 | 7.00 (407.25%) | Beli | 1.67 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Jan 2026 | Pengumuman | Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock |
| 21 Jan 2026 | Pengumuman | Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock |
| 15 Jan 2026 | Pengumuman | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration |
| 13 Jan 2026 | Pengumuman | Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data |
| 12 Jan 2026 | Pengumuman | Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy |
| 09 Jan 2026 | Pengumuman | Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference |
| 10 Dec 2025 | Pengumuman | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |